Infant fish oil study
The immunomodulatory effects of omega-3 polyunsaturated fatty acids : role in allergy prevention
Prof Susan Prescott
360 participants
Jun 1, 2005
Interventional
Conditions
Summary
In this study we will compare the effects of fish oil (n=165) or placebo (n=165) in early infancy (from 0-6 months of age) on the risk of developing allergic sensitisation or allergic disease in early childhood. Both study groups will include children deemed to be at high risk of allergic disease (based on maternal allergy history).
Eligibility
Inclusion Criteria1
- maternal asthma or hayfever, and atopy confirmed by skin testing (to common allergens); and 2) maternal age
Exclusion Criteria1
- Infants will be excluded if: 1) their mother’s normal dietary intake exceeds 2 meals of fish per week 2) there are any significant pregnancy or neonatal complications including prematurity of < 36 weeks), or 3) parental smoking.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Children will be randomised to receive n-3 rich fish oil (280mg docosahexanoic acid [DHA]/day; 110mg eicosapentanoic acid [EPA]/day orally; Meg 3 Ocean Nutrition, Canada) daily for the first 6 months of life. The capsules are identical in appearance. Peppermint flavour has been added to both fish oil and placebo capsules.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12606000281594